HomeCompareSGXXF vs ABBV

SGXXF vs ABBV: Dividend Comparison 2026

SGXXF yields 5000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGXXF wins by $4.651129742658086e+43M in total portfolio value
10 years
SGXXF
SGXXF
● Live price
5000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.651129742658086e+43M
Annual income
$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00
Full SGXXF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SGXXF vs ABBV

📍 SGXXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGXXFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGXXF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGXXF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGXXF
Annual income on $10K today (after 15% tax)
$425,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$39,533,047,462,834,250,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SGXXF beats the other by $39,533,047,462,834,250,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGXXF + ABBV for your $10,000?

SGXXF: 50%ABBV: 50%
100% ABBV50/50100% SGXXF
Portfolio after 10yr
$2.325564871329043e+43M
Annual income
$23,254,733,801,667,206,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SGXXF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGXXF buys
0
ABBV buys
0
No recent congressional trades found for SGXXF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGXXFABBV
Forward yield5000000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.651129742658086e+43M$102.3K
Annual income after 10y$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$4.651117771440442e+43M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SGXXF vs ABBV ($10,000, DRIP)

YearSGXXF PortfolioSGXXF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$500,010,700$500,000,000.00$11,550$430.00+$500.00MSGXXF
2$23,365,520,992,757$23,364,985,981,308.41$13,472$627.96+$23365520.98MSGXXF
3$1,020,442,548,175,215,100$1,020,417,547,067,752,800.00$15,906$926.08+$1020442548175.20MSGXXF
4$41,650,346,151,752,480,000,000$41,649,254,278,225,940,000,000.00$19,071$1,382.55+$41650346151752480.00MSGXXF
5$1,588,787,048,835,084,000,000,000,000$1,588,742,482,964,701,800,000,000,000.00$23,302$2,095.81+$1.588787048835084e+21MSGXXF
6$56,640,860,400,245,200,000,000,000,000,000$56,639,160,398,102,940,000,000,000,000,000.00$29,150$3,237.93+$5.66408604002452e+25MSGXXF
7$1,887,170,449,619,629,000,000,000,000,000,000,000$1,887,109,843,899,000,500,000,000,000,000,000,000.00$37,536$5,121.41+$1.887170449619629e+30MSGXXF
8$58,763,764,792,023,670,000,000,000,000,000,000,000,000$58,761,745,519,642,570,000,000,000,000,000,000,000,000.00$50,079$8,338.38+$5.876376479202367e+34MSGXXF
9$1,710,115,183,602,138,000,000,000,000,000,000,000,000,000,000$1,710,052,306,373,811,000,000,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$1.710115183602138e+39MSGXXF
10$46,511,297,426,580,864,000,000,000,000,000,000,000,000,000,000,000$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$4.651129742658086e+43MSGXXF

SGXXF vs ABBV: Complete Analysis 2026

SGXXFStock

Sound Global Ltd., an investment holding company, provides water and wastewater treatment solutions in the People's Republic of China, Singapore, and Bangladesh. It operates in three segments: Turnkey Projects and Services; Equipment Fabrications; and Operations and Maintenance of Water Supply and Wastewater Treatment Facilities. The company designs, constructs, operates, and maintains water and wastewater treatment facilities; and manufactures water and wastewater treatment equipment. It is also involved in the municipal water supply, wastewater treatment, and water recycling and reuse; research and development of water treatment technologies and provision of services of technology consultation; labor subcontracting activities; and leasing of construction machinery and equipment. In addition, the company plans, designs, constructs, and manages industrial zone water management systems, municipal wastewater projects, and water supply projects; and offers integrated solutions in various fields, such as industrial water supply, desalination, and industrial wastewater treatment and cyclical reuse, as well as centralized treatment for water supply and drainage in industrial zones. Further, it engages in the integration of water supply and drainage in villages and small towns; industrial and residential properties construction, and engineering design and construction activities; sale of building materials; leasing of properties; and computer software development activities. Additionally, the company offers equity investment management and consulting services; and property management and maintenance services. The company was formerly known as Epure International Ltd. and changed its name to Sound Global Ltd. in May 2010. Sound Global Ltd. was founded in 1993 and is based in Singapore. Sound Global Ltd. is a subsidiary of Sound Water (BVI) Limited.

Full SGXXF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SGXXF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGXXF vs SCHDSGXXF vs JEPISGXXF vs OSGXXF vs KOSGXXF vs MAINSGXXF vs JNJSGXXF vs MRKSGXXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.